



UNITED STATES PATENT AND TRADEMARK OFFICE

UNITED STATES DEPARTMENT OF COMMERCE  
United States Patent and Trademark Office  
Address: COMMISSIONER OF PATENTS AND TRADEMARKS  
Washington, D.C. 20231  
[www.uspto.gov](http://www.uspto.gov)

APPLICATION NO.	FILING DATE	FIRST NAMED INVENTOR	ATTORNEY DOCKET NO.	CONFIRMATION NO.
09/465,338	12/17/1999	Kenneth S. Albert	PT-1817	8786

23607 7590 02/21/2002

IVOR M HUGHES  
175 COMMERCE VALLEY DRIVE WEST  
SUITE 200  
THORNHILL, ON L3T7P6  
CANADA

[REDACTED] EXAMINER

PULLIAM, AMY E

[REDACTED] ART UNIT [REDACTED] PAPER NUMBER

1615

DATE MAILED: 02/21/2002

Please find below and/or attached an Office communication concerning this application or proceeding.

<b>Office Action Summary</b>	<b>Application No.</b>	<b>Applicant(s)</b>
	09/465,338	ALBERT ET AL.
	<b>Examiner</b>	<b>Art Unit</b>
	Amy E Pulliam	1615

-- The MAILING DATE of this communication appears on the cover sheet with the correspondence address --

### Period for Reply

A SHORTENED STATUTORY PERIOD FOR REPLY IS SET TO EXPIRE 3 MONTH(S) FROM THE MAILING DATE OF THIS COMMUNICATION.

- Extensions of time may be available under the provisions of 37 CFR 1.136(a). In no event, however, may a reply be timely filed after SIX (6) MONTHS from the mailing date of this communication.
- If the period for reply specified above is less than thirty (30) days, a reply within the statutory minimum of thirty (30) days will be considered timely.
- If NO period for reply is specified above, the maximum statutory period will apply and will expire SIX (6) MONTHS from the mailing date of this communication.
- Failure to reply within the set or extended period for reply will, by statute, cause the application to become ABANDONED (35 U.S.C. § 133).
- Any reply received by the Office later than three months after the mailing date of this communication, even if timely filed, may reduce any earned patent term adjustment. See 37 CFR 1.704(b).

### Status

1) Responsive to communication(s) filed on 02 November 2001.

2a) This action is FINAL.                    2b) This action is non-final.

3) Since this application is in condition for allowance except for formal matters, prosecution as to the merits is closed in accordance with the practice under *Ex parte Quayle*, 1935 C.D. 11, 453 O.G. 213.

### Disposition of Claims

4) Claim(s) 1-110 is/are pending in the application.

4a) Of the above claim(s) \_\_\_\_\_ is/are withdrawn from consideration.

5) Claim(s) \_\_\_\_\_ is/are allowed.

6) Claim(s) 1-47,50-59 and 61-110 is/are rejected.

7) Claim(s) 48, 49, 60 is/are objected to.

8) Claim(s) \_\_\_\_\_ are subject to restriction and/or election requirement.

### Application Papers

9) The specification is objected to by the Examiner.

10) The drawing(s) filed on \_\_\_\_\_ is/are: a) accepted or b) objected to by the Examiner.  
Applicant may not request that any objection to the drawing(s) be held in abeyance. See 37 CFR 1.85(a).

11) The proposed drawing correction filed on \_\_\_\_\_ is: a) approved b) disapproved by the Examiner.  
If approved, corrected drawings are required in reply to this Office action.

12) The oath or declaration is objected to by the Examiner.

### Priority under 35 U.S.C. §§ 119 and 120

13) Acknowledgment is made of a claim for foreign priority under 35 U.S.C. § 119(a)-(d) or (f).

a) All b) Some \* c) None of:

1. Certified copies of the priority documents have been received.
2. Certified copies of the priority documents have been received in Application No. \_\_\_\_\_.
3. Copies of the certified copies of the priority documents have been received in this National Stage application from the International Bureau (PCT Rule 17.2(a)).

\* See the attached detailed Office action for a list of the certified copies not received.

14) Acknowledgment is made of a claim for domestic priority under 35 U.S.C. § 119(e) (to a provisional application).  
a) The translation of the foreign language provisional application has been received.

15) Acknowledgment is made of a claim for domestic priority under 35 U.S.C. §§ 120 and/or 121.

### Attachment(s)

1) <input type="checkbox"/> Notice of References Cited (PTO-892)	4) <input type="checkbox"/> Interview Summary (PTO-413) Paper No(s). _____
2) <input type="checkbox"/> Notice of Draftsperson's Patent Drawing Review (PTO-948)	5) <input type="checkbox"/> Notice of Informal Patent Application (PTO-152)
3) <input type="checkbox"/> Information Disclosure Statement(s) (PTO-1449) Paper No(s) _____	6) <input type="checkbox"/> Other: _____

**DETAILED ACTION**

Receipt is acknowledged of the Amendment D, received November 2, 2001.

***Allowable Subject Matter***

Claims 48, 49, and 60 would be allowable if rewritten or amended to overcome the rejection(s) under 35 U.S.C. 112, second paragraph, set forth in this Office action.

The allowance of claims 40, 44, 46, 50, 51, 52, and 53 is hereby withdrawn for the reasons stated below.

***Claim Rejections - 35 USC § 112***

The following is a quotation of the second paragraph of 35 U.S.C. 112:

The specification shall conclude with one or more claims particularly pointing out and distinctly claiming the subject matter which the applicant regards as his invention.

Claims 18, 36, 50, 52, 53, 56, 57, 59, and 60-62 are rejected under 35 U.S.C. 112, second paragraph, as being indefinite for failing to particularly point out and distinctly claim the subject matter which applicant regards as the invention.

Claims 50, 52, 53, 56, 57, 59, and 60-62 contain the term "suitable," or are dependant upon a claim which contains the term. The term "suitable" in the claims is a relative term which renders the claim indefinite. The term is not defined by the claim, the specification does not provide a standard for ascertaining the requisite degree, and one of ordinary skill in the art would not be reasonably apprised of the scope of the invention. Appropriate correction is required.

Claims 18 and 36 contain the phrase "and the like" or are dependant upon a claim which contains the phrase. The phrase " and the like" in the claims is a relative term which renders the claim indefinite. The phrase is not defined by the claim, the specification does not provide a standard for ascertaining the requisite degree, and one of ordinary skill in the art would not be reasonably apprised of the scope of the invention. Appropriate correction is required.

***Claim Rejections - 35 USC § 102***

The following is a quotation of the appropriate paragraphs of 35 U.S.C. 102 that form the basis for the rejections under this section made in this Office action:

A person shall be entitled to a patent unless –

(b) the invention was patented or described in a printed publication in this or a foreign country or in public use or on sale in this country, more than one year prior to the date of application for patent in the United States.

Claims 1-15, 17, 19-37, 39, 43, and 63-78 are rejected under 35 U.S.C. 102(b) as being anticipated by EPA 856 313 to Geoghegan *et al.* ('313).

EPA '313 discloses a controlled absorption diltiazem pellet formulation for oral administration to control hypertension and angina comprising a core of diltiazem or a pharmaceutically acceptable salt thereof, and a multilayer membrane surrounding the core and containing both a water insoluble and a water soluble polymer (abstract). EPA '313 further discloses that the formulation is preferred as a once-daily product to be administered before bedtime, and to be released at the following rates:

- a. from 0 to 35% after 2 hours
- b. from 4 to 45% after 4 hours

- c. from 30 to 75% after 8 hours
- d. from 60 to 95% after 13 hours
- e. not less than 85% after 24 hours.

These release rates overlap those claimed by applicant in the instant application.

Further, EPA '313 teaches that the water insoluble polymer can be replaced by a copolymer of acrylic and methacrylic acid esters (p 28, claim 10), and that the water soluble polymer can be HPMC (p 28, claim 7). EPA '313 also teaches that the core may comprise an organic acid, a lubricant (p 5, I 15-29), and other pharmaceutically acceptable components. In addition, throughout the examples, EPA '313 teaches varying amounts of active ingredient, including 120, 240, and 90 mg. Further, EPA '313 teaches tablet, pellet, and capsule formulations (exs. 8, 14, 21). Although EPA '313 does not disclose the exact release rates claimed by applicant, the ranges claimed fall within the range disclosed by EPA '313, and therefore are rendered obvious by the reference.

#### ***Claim Rejections - 35 USC § 103***

The following is a quotation of 35 U.S.C. 103(a) which forms the basis for all obviousness rejections set forth in this Office action:

(a) A patent may not be obtained though the invention is not identically disclosed or described as set forth in section 102 of this title, if the differences between the subject matter sought to be patented and the prior art are such that the subject matter as a whole would have been obvious at the time the invention was made to a person having ordinary skill in the art to which said subject matter pertains. Patentability shall not be negated by the manner in which the invention was made.

Claims 1-47, 50-59, and 61-110 are rejected under 35 U.S.C. 103(a) as being unpatentable over EPA 856 313 to Geoghegan et al. ('313).

EPA '313 does not teach all of the specific amounts of Diltiazem present in the formulation, nor do they teach the specific wetting agent claimed by applicant. However, the formulation disclosed in EPA '313 does teach a varied range of the amount of active ingredient, as well as the presence of additional additives, such as lubricants. Further, the formulation also releases the drug at the same rate as that claimed by applicant, therefore, it appears that these limitations do not render any unexpected results. It is the position of the examiner that these are limitations which would be routinely determined by one of ordinary skill through minimal experimentation, as being suitable, absent the presentation of some unusual and/ or unexpected results. The results must be based on the specific limitations.

Furthermore, it is the position of the examiner that EP '313 teaches the generic concept of the invention, as well as the suggestion to manipulate the formulation to result in varying dissolution rates and Cmax values. One of ordinary skill in the art would have been motivated to manipulate the formulation based on the specifics of the desired formulation. The expected result would be a successful pharmaceutical formulation. Therefore, this invention as a whole would have been *prima facie* obvious to one of ordinary skill in the art at the time the invention was made.

Applicant's arguments have been fully considered but are not found persuasive. Applicant has submitted evidence and scientific demonstrations to prove that the degree of fluctuation is not dose dependant. Applicant argues that this evidence makes the earlier submission of evidence, regarding the unexpected results of the 300 mg dosage

Art Unit: 1615

form, applicable to all dosage forms. The examiner respectfully disagrees with applicant's argument. First, the data and evidence submitted by applicant does not overcome the new 102 rejection. This rejection can not be overcome by a showing of unexpected results. Second, many of the claims rejected under 103, are rejected as obvious rather than anticipated because they have dosage amounts which are not expressly taught in the EP '313 reference. However, applicant states that Degree of Fluctuation is dose independent. In that case, the claims which are rendered obvious rather than anticipated due only to a different dosage amount, are clearly obvious over the EP'313 reference. The reference teaches the same drug, for the same purpose, with overlapping release rates. If dosage amounts have no impact on the unexpected results of applicant's invention, and the only difference between the reference and the instant claims is the dosage amount, then no unexpected results have been shown. Furthermore, applicant has provided no evidence as to what causes the "unexpected results." As stated before, the EP'313 reference is an anticipatory reference over some of applicant's claims. However, applicant is claiming unexpected results even for these claims. In this case, it is necessary for applicant to include, in the independent composition claims, what additions to the composition render the unexpected results.

Additionally, during the phone conversation of February 7, 2002, Mr. Hughes stated that applicant believes the EP '313 reference is not anticipatory because it does not teach the claimed Tmax. However, the examiner directs applicant's attention to example 1 of the reference, which teaches a Tmax of 14.00 hours (p 20), and teaches a release profile which falls within applicant's claimed ranges (p 8).

Claims 1-47, 50-59, 61, and 62 are rejected under 35 U.S.C. 103(a) as being unpatentable over WO 93/00093 to Deboeck *et al.* ('093). WO '093 discloses an extended release galenical form of Diltiazem or a pharmaceutically acceptable salt, with a wetting agent, coated with a microporous membrane comprising at least a water soluble polymer and a pharmaceutically acceptable adjuvant. WO '093 further teaches that the composition comprises beads containing between 120 and 480 mg of the active ingredient, with the wetting agent, and the beads are coated with the microporous membrane (p 19, claim 1). WO '093 further teaches that the water soluble polymer or copolymer can include HPMC and Eudragit (p 8, I 21-28). Further, WO '093 teaches that the following ingredients are included in the formulation: wetting agents such as fatty acid esters of saccharose (2-20%), microcrystalline cellulose (5-25%), polyvinylpyrrolidone (1-15%), titanium oxide, surfactants such as tween, antifoaming agents, magnesium stearate, and talc (see pages 8-10). These are the ingredients disclosed by applicant as being present in the formulation. WO '093 also teaches that the formulation is for once daily administration.

WO '093 does not teach the exact rates of release as claimed by applicant, nor do they discuss the rates of release after 8 hours, nor do they disclose all of the specific amounts of the above mentioned ingredients. However, WO '093 does teach overlapping rates of release to those claimed by applicant, and they do teach the same ingredients as claimed by applicant. It is the position of the examiner that the present application is not patentably distinct from WO '093, as they contain the same

ingredients, in the same formulation, with overlapping rates of release, even though WO '093 does not disclose the specific amounts of all the ingredients. It is the position of the examiner that the specific amounts of those ingredients which are not disclosed in WO '093 are limitations which would be routinely determined by one of ordinary skill in the art through minimal experimentation, absent the presentation of some unusual and/or unexpected results. The results must be those that accrue from the specific limitations. Therefore it would have been obvious to one of ordinary skill in the art at the time the invention was made to create a controlled release formulation of Diltiazem, based on the teachings of WO '093, and experiment with and vary the specific amounts of the ingredients, in order to achieve the desired rate of release.

Applicant argues that WO '093 does not teach the exact Cmax and Tmax as claimed by applicant. The examiner acknowledges this fact, and this is why the WO '093 reference is used as an obviousness reference, not an anticipation reference. It is the position of the examiner that because WO '093 contains the same ingredients in the same formulation, with overlapping release rates, applicant's invention is not patentably distinct from the prior art; therefore, this rejection is maintained.

Furthermore, applicant argues that the peak to trough variance for the WO '093 reference (which corresponds to Tiazac) is much larger than that of applicant's formulation. Applicant has provided evidence to reinforce this statement. However, the examiner respectfully disagrees as the data regarding Tiazac is concerning a 240 mg formulation, and the data regarding applicant's claimed formulation is based on a 300

Art Unit: 1615

mg capsule. Therefore, this comparison is not persuasive, and the rejection is maintained.

***Conclusion***

Any inquiry concerning this communication or earlier communications from the examiner should be directed to Amy E Pulliam whose telephone number is 703-308-4710. The examiner can normally be reached on Mon-Thurs 7:30-5:00, Alternate Fri 8:30-5:00.

If attempts to reach the examiner by telephone are unsuccessful, the examiner's supervisor, Thurman Page can be reached on 703-308-2927. The fax phone numbers for the organization where this application or proceeding is assigned are 703-305-3592 for regular communications and 703-305-3592 for After Final communications.

Any inquiry of a general nature or relating to the status of this application or proceeding should be directed to the receptionist whose telephone number is 703-308-1235.

aep  
February 20, 2002

THURMAN K PAGE  
SUPERVISORY PATENT EXAMINER  
TECHNOLOGY CENTER 1600  
*[Signature]*